UPT Perpustakaan Universitas Andalas
Repositori PerpustakaanUniversitas Andalas
 

PENGARUH PROGRAM LATIHAN FISIK TERHADAP RESISTENSI VASKULAR PARU SECARA EKOKARDIOGRAFI PADA PASIEN DENGAN HIPERTENSI ARTERI PULMONAL DI RSUP DR. M. DJAMIL PADANG

dc.contributor.advisorMEFRI, YANNI
dc.contributor.authorPutri, Maulina
dc.date.accessioned2026-09-24T23:41:05Z
dc.date.issued2023-11-29
dc.descriptiondr. MEFRI YANNI, Sp.JP(K)
dc.description.abstractABSTRAK Nama : Putri Maulina Program Studi : Ilmu Penyakit Jantung dan Pembuluh Darah Judul : Pengaruh Program Latihan Fisik Terhadap Resistensi Vaskular Paru Secara Ekokardiografi Pada Pasien Dengan Hipertensi Arteri Pulmonal di RSUP Dr. M. Djamil Padang Latar Belakang: Hipertensi arteri pulmonal (HAP) disebabkan oleh meningkatnya resistensi vaskular paru (pulmonary vascular resistance, PVR) dan tekanan rerata arteri pulmonal (mean pulmonary artery pressure, mPAP). Program latihan fisik merupakan modalitas terapi tambahan yang dapat menghambat progresivitas penyakit pada pasien HAP, namun saat ini belum ada program latihan yang terstandar. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui pengaruh latihan fisik terhadap resistensi vaskular paru pada pasien dengan HAP. Metode Penelitian: Penelitian ini merupakan uji klinis non-random pada pasien HAP dewasa yang dibagi menjadi kelompok intervensi yang dilakukan latihan fisik dan kelompok kontrol. Data karakteristik dasar, data karakteristik hemodinamik dan ekokardiografi dan PVR sebelum dan setelah dilakukan latihan fisik selama empat minggu (20 sesi, lima kali seminggu) didokumentasikan. Uji normalitas Shapiro-Wilk dilakukan sebelum menganalisis data numerik dan dilanjutkan dengan T-test independen atau uji Mann-Whitney untuk mengetahui perbedaan di antara kelompok. Hasil Penelitian: Subjek penelitian ini berjumlah 32 orang pasien dengan HAP, yang dibagi menjadi 16 orang subjek untuk masing-masing kelompok. Pada karakteristik dasar subjek penelitian didapatkan jenis kelamin perempuan sebanyak 22 orang (68,75%) dan laki- laki sebanyak 10 orang (31,25%) dengan rentang usia 18-55 tahun. Analisis statistik menunjukkan tidak terdapat perbedaan yang signifikan pada karakteristik dasar, data hemodinamik dan ekokardiografi pada kedua kelompok. Selanjutnya, pengukuran PVR secara ekokardiografi awal tidak ditemukan perbedaan yang signifikan di antara kelompok intervensi dan kontrol (3,53±1,43 (95% CI: 1,82-6,92) vs 3,68±1,48 (95% CI: 1,46-7,46), ¬p-value > 0,05. Setelah program latihan 4 minggu, kelompok intervensi menunjukkan nilai PVR yang dinilai dengan ekokardiografi yang lebih rendah jika dibandingkan dengan kelompok kontrol (2,20±0,83 (95% CI: 1,10-4,70) vs 3,67±1,61 (95% CI: 1,35-7,56), p-value < 0,05). Sehingga didapatkan Δ PVR yang lebih rendah secara signifikan pada kelompok intervensi dibandingkan dengan kelompok kontrol (-1,36±0,67 (95% CI: -0,33-(-2,85)) vs -0,34±0,30 (95% CI: -0,39-(0,63)), p-value < 0,05) Kesimpulan: Program latihan fisik selama 4 minggu dapat menurunkan resistensi vaskular paru pada pasien HAP.
dc.identifier.urihttps://ailib.my.id/handle/123456789/73176
dc.language.isoid
dc.publisherUniversitas Andalas
dc.subjecthipertensi arteri pulmonal
dc.subjectlatihan fisik
dc.subjectekokardiografi
dc.subjectresistensi vaskular paru
dc.subject.classificationR Medicine (General)
dc.titlePENGARUH PROGRAM LATIHAN FISIK TERHADAP RESISTENSI VASKULAR PARU SECARA EKOKARDIOGRAFI PADA PASIEN DENGAN HIPERTENSI ARTERI PULMONAL DI RSUP DR. M. DJAMIL PADANG
dc.typeThesis
dcterms.dateSubmitted2023-12-28
dcterms.referencesDAFTAR PUSTAKA 1. Emmons-Bell S, Johnson C, Boon-Dooley A, Corris PA, Leary PJ, Rich S, et al. Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. Pulmonary Circulation. 2022 (12): 1-15. 2. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). European Heart Journal. 2022;43(38):3618-731. 3. Zeng X, Chen H, Ruan H, Ye X, Li J, Hong C. Effectiveness and safety of exercise training and rehabilitation in pulmonary hypertension: a systematic review and meta-analysis. Journal of Thoracic Disease. 2020; 12(5): 2691-705. 4. Dinarti LK, Hartopo BA, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The Congenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovascular Disorders. 2020; 20: 1-11. 5. Raihani MU, Yanni M, Asri E, et al. Gambaran Karakteristik Pasien Hipertensi Arteri Pulmonal di RSUP Dr. M. Djamil Padang Tahun 2017-2021. Universitas Andalas, 2022. 6. Vecchia LA, Busotti M. Exercise Training in Pulmonary Arterial Hypertension. Journal of Thoracic Disease. 2018; 10(1): 508-21. 7. Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: new pathophysiological insights and emerging therapeutic targets. The international journal of biochemistry & cell biology. 2018; 104: 9-13. 8. Wright BS, Dwyer N, Celermajer D, Kritharides L, Marwick T. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC. 2016 ; 733-46. 9. Miotti C, Papa S, Manzi G, Scoccia G, Luongo F, Toto F, et al. The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification : The Missing Piece. J. Clin. Med. 2021(10); 1-9. 10. Naing P, Kuppusamy H, Scalia G, Hillis GS, Playford D. Non-Invasive Assessment of Pulmonary Vascular Resistance in Pulmonary Hypertension: Current Knowledge and Future Direction. Heart, Lung, and Circulation. 2017 (26); 323-30. 11. Hayama H, Moroi M, Akahane A, Uejima t, Hara H, Hiroi Y. A Novel Non-Invasive Method for Estimating Elevated Pulmonary Vascular Resistance Based on Echocardiographic Assessment of Pulmonary Artery Wave Reflection. Circulation Journal. 2022; 86: 947-55. 12. Panda AL, Nasution AN, Soesanto AM, Lubis AC, Hartopo AB, Saboe A, et al. Pedoman Diagnosis dan Tatalaksana Hipertensi Pulmonal. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2021; 1-60. 13. Dong C, Li Y. Exercise Rehabilitation Training in Patients With Pulmonary hypertension : A Review. Heart, Lung, and Circulation. 2022 (21); 1341-8. 14. Tobal R, Potjewijd J, Van Empel VPM, Yserman R, Schurgers LJ, Reutelingsperger CP, et al. Vascular Remodeling in Pulmonary Arterial Hypertension: The Potential Involvement of Innate and Adaptive Immunity. Front. Med. 2021 (8); 1-14 15. Colombo R, Siqueira R, Becker CU, et al. Effects of exercise on monocrotalineinduced changes in right heart function and pulmonary artery remodeling in rats. Canadian journal of physiology and pharmacology 2013;91:38-44 16. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. European heart journal. 2016;37(1):35-44. 17. Schemurly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanism of disease: pulmonary artery hypertension. Nat. Rev. Cardiol. 2011 (8); 443-55. 18. Ridwan M, Diniati H, Putri CJE, Habibie YA, Sariningrum HA. Role of Exercise Training in Pulmonary hypertension : A Review Article. Bali Medical Journal. 2021 (10); 2302-14. 19. Laveneziana P, Garcia G, Joureau B, Nicolas-Jilwan F, Brahimi T, Laviolette L, et al. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal. 2013;41(3):578-87 20. Malenfant S, Potus F, Mainguy V, Leblanc E, Malenfant M, Ribeiro F, et al. Impaired skeletal muscle oxygenation and exercise tolerance in pulmonary hypertension. Med Sci Sports Exerc. 2015;47(11):2273-82. 21. Eichstaedt CA, Benjamin N, Xanthouli P, Marra AM, Grünig E. The role of rehabilitation in patients with pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine. 2019;25(5):398-404. 22. Weissmann N, Peters DM, Klopping C, Kruger K, Pilat C, Katta, S, et al. Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise in mice. Am. J. Physiol Lung Cell Mol Physiol. 2014; L986-5. 23. Ley S, Fink C, Risse F, Ehlken N, Fischer C, ley J, et al. Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension. European Society of Radiology. 2013; 324-31. 24. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. Circulation 2006; 114: 1482–1489. 25. Zhang X, Xu D. Effect of exercise rehabilitaton training on patients with pulmonary hypertension. Pulmonary Circulation. 2020; 10 (3): 1-8. 26. Handoko ML, de Man F.S, Happe CM, Schalij I, Musters RJP, Westerhof N. Opposite Effects of Training in Rats With Stable and Progressive Pulmonary Hypertension. Circulation. 2009; 42-9. 27. Deng J. Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. J Cardiothorac Surg. 2021;311. 28. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. 29. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, lester SJ. A Simple Method for Noninvasive Estimation of Pulmonary Vascular Resistance. Journal of American College of Cardiology. 2003; 1021-6. 30. Sumimoto K, Tanaka H, Mukai J, Yamashita K, Yanaka Y, Shono A, et al. Optimal Cut-Off Tricuspid Regurgitation Velocity According to the New Definition of Pulmonary Hypertension. Circulation Report. 2020; 1-5. 31. Marra AM, Naeije R, Ferrara F, Vriz O, Stanziola AA, D’Alto M, et al. Reference Ranges and Determinants of Tricuspid Regurgitation Velocity in healthy Adults Assessed by Two-Dimensional Doppler Echocardiography. Respiration. 2018; 425-33 32. Miot HA. Sample size in clinical and experimental trials. Jornal Vascular Brasileiro. 2011;10:275-8. 33. PERKI. Panduan Rehabilitasi Kardiovaskular. 1st ed. Jakarta: PERHIMPUNAN DOKTER SPESIALIS KARDIOVASKULAR INDONESIA, 2019. 34. Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumanis MC, et al. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev. 2021;1-20. 35. Martin YN, Pabelick CM. Sex differences in the pulmonary circulation: implications for pulmonary hypertension. Am J Physiol Heart Cir. 2014: h1255-60. 36. White K,, Dempise Y, Nilsen M, Wrigt AF, Loughlin L, Maclean MR. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Resp. 2011; (90)2: 373-82. 37. Dai-Do D, Espinosa E, Liu G, Rabelink TJ, Julmy F, Yang Z, et al. 17 beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effect in cells from postmenopausal females and in males. Cardiovasc Res. 1996; 32(5): 980-5. 38. Hoeper MM, Gibbs JSR. The changing landscape of pulmonary arterial hypertension and implications for patient care. European Respiratory Revew. 2014: 450-7. 39. Londoño A, Conde R, Pacheco M, Velasquez CJ, Gomez-Palau R, Tiga D, et al. Underweight/overweight syndrome in patients with pulmonary hypertension in Colombia: a prevalence study. European Respiratory Journal 2022; 60 (suppl 66) 869. 40. Kwant CT, Van der Horst FA, Bogaard HJ, De Man FS, Noordegraaf AV. Nutritional status in pulmonary arterial hypertension. Pulmonary Circulation. 2022: e12173. 41. D’Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2-12; 21: 328-37 42. Kiss T, Kovacs K, Komocsi A, Tornyos A, Zalan P, Sumegi B, et al. Novel mechaniss of Sildenafil in Pulmonary Hypertension Involving Cytokines/Chemokines, MAP Kinase and Akt. PLOS ONE. 2014; e104890. 43. Shi Q, Wang Z, Yang N, Ma Y, chen Y, Wei H, et al. Sildenafil for adult Asian pastients with pulmonary arterial hypertension: a systematic review and meta-analysis. Annals of Palliative Medicine. 2022; 339-49. 44. Bersohn MM, Turner MP, Traiger GL, et al. Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension. Chest 2013; 144: 959– 965. 45. Van der Feen DE, Bartelds B, de Boer RA, Berger RM. Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart. 2018; 1-7. 46. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GH, et al. 2020 ESC Guidelines for management of adult congenital heart disease. 2021: 563-654.
local.eprints.dirdisk0/00/46/00/81
local.eprints.divisionS2
local.eprints.id460081
local.eprints.typethesis/masters
local.eprints.urihttp://scholar.unand.ac.id/460081/
local.fakultasPascasarjana (S2)
local.identifier.nim1950311304
local.thesis.levelTesis

Files

Collections